Scholarlink

Background <p>Ireland is a globally recognised trading nation, providing high-quality meat, milk, and dairy products. To remain viable and grow over time, the Irish agricultural sector must prioritise animal health to maximise productivity, as parasite infections represent a major production-limiting issue.</p> Objective <p>This study aimed to formulate plasticised solid dispersion tablets containing oxfendazole (OXF), a broad-spectrum benzimidazole anthelmintic, with improved dissolution behaviour and an extended-release profile. The work addresses the challenge posed by the poor aqueous solubility and limited dissolution of OXF, factors that restrict its therapeutic performance, and introduces a semi-continuous manufacturing strategy to overcome these limitations.</p> Methods <p>An innovative pharmaceutical approach employing a semi-continuous manufacturing process that integrates hot-melt extrusion (HME) with micro-injection moulding (µIM) was investigated. Two solid dispersion formulations were developed and evaluated: SDF 1, consisting of PEO 95% and OXF 5% (<i>w</i>/<i>w</i>), and SDF 2, consisting of PEO 52.3%, OXF 2.7%, and PCL 45% (<i>w</i>/<i>w/w</i>).</p> Results <p>In vitro drug release studies using high-performance liquid chromatography (HPLC) showed that SDF 1 achieved an ~ 8-fold enhancement in drug dissolution compared to a commercial OXF tablet. SDF 2 demonstrated a ~ 4-fold increase in drug release over a three-day period, attributable to its extended-release characteristics. Biocompatibility was assessed through cell viability assays, confirming that the plasticised tablets produced by melt-processing techniques are non-toxic.</p> Conclusion <p>HME coupled with µIM are novel pharmaceutical manufacturing techniques with potential to scale up to mass production. These advanced OXF formulations present a promising therapeutic strategy for the control of helminthiasis in grass-fed cattle, supporting enhanced animal health and agricultural sustainability.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Development of Novel Oral Extended-Release Anthelmintic Formulations for Grazing Cattle

  • 期刊论文

  • 发表日期：

    2026年1月3日

查看全文
  • Gilberto Silva Nunes Bezerra,
  • Bianca Simonassi-Paiva,
  • Declan Colbert,
  • Joseph Geever,
  • Luke Geever

摘要

Background

Ireland is a globally recognised trading nation, providing high-quality meat, milk, and dairy products. To remain viable and grow over time, the Irish agricultural sector must prioritise animal health to maximise productivity, as parasite infections represent a major production-limiting issue.

Objective

This study aimed to formulate plasticised solid dispersion tablets containing oxfendazole (OXF), a broad-spectrum benzimidazole anthelmintic, with improved dissolution behaviour and an extended-release profile. The work addresses the challenge posed by the poor aqueous solubility and limited dissolution of OXF, factors that restrict its therapeutic performance, and introduces a semi-continuous manufacturing strategy to overcome these limitations.

Methods

An innovative pharmaceutical approach employing a semi-continuous manufacturing process that integrates hot-melt extrusion (HME) with micro-injection moulding (µIM) was investigated. Two solid dispersion formulations were developed and evaluated: SDF 1, consisting of PEO 95% and OXF 5% (w/w), and SDF 2, consisting of PEO 52.3%, OXF 2.7%, and PCL 45% (w/w/w).

Results

In vitro drug release studies using high-performance liquid chromatography (HPLC) showed that SDF 1 achieved an ~ 8-fold enhancement in drug dissolution compared to a commercial OXF tablet. SDF 2 demonstrated a ~ 4-fold increase in drug release over a three-day period, attributable to its extended-release characteristics. Biocompatibility was assessed through cell viability assays, confirming that the plasticised tablets produced by melt-processing techniques are non-toxic.

Conclusion

HME coupled with µIM are novel pharmaceutical manufacturing techniques with potential to scale up to mass production. These advanced OXF formulations present a promising therapeutic strategy for the control of helminthiasis in grass-fed cattle, supporting enhanced animal health and agricultural sustainability.